MissionIRNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Sequire Clean Tech & EV Virtual Conference to Shine the Spotlight on Industry Experts and Trends

 SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that it will host the first Sequire Clean Tech & EV Conference, slated to take place from 8 a.m. through 5 p.m. ET on Dec. 6, 2021. The one-day investor event will feature prominent electric vehicles, energy and power, materials and chemicals, and food and agriculture companies. As businesses and consumers worldwide gravitate toward more sustainable practices, SRAX is excited to host a full day of networking and learning with the premier innovators in the clean tech space. “With the new infrastructure bill in place, we can hope to see adoption and growth within the clean technology and electric vehicle industry in the years to come,” said Morgan-Lea Fogg, community development director at SRAX. “We are looking forward to exploring this further within our panels and hearing from experts on trends as we host you for the last Sequire event of the year.”

To view the full press release, visit https://ibn.fm/VIsUA

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at  http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks — Save Foods Inc. (NASDAQ: SVFD) Sees Initial Commercial Sale of PeroSTAR Bell-Pepper Treatment

 Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, announced that it has received its first commercial sale of its PeroSTAR(TM) product. Two Israel-based, bell-pepper packing houses have ordered the product, which is formulated to ensure the safety and maximum shelf life of produce before it is exported. The packing houses tried the PeroSTAR treatment initially and, following positive results, decided to fully integrate the product into their treatment process. The packing houses are located in the Arava region, which produces approximately 60% of the fresh vegetables exported by Israel. Bell pepper, which are sold primarily to Russia, North America and the United Kingdom, are the leading export. This first commercial sale comes as the company also received regulatory approval of its product from the California Department of Pesticide Regulation (“CDPR”). “We are excited to see the first large-scale commercial implementation of our product for the bell pepper market, especially here in the heart of Israel’s thriving agriculture industry,” said Save Foods CEO Dan Sztybel in the press release. “We believe that the use of Save Foods’ treatment will help the Arava packing houses export produce of the highest quality without fungicides or a trace of hazardous residue.”

To view the full press release, visit https://ibn.fm/8Jf2M

About Save Foods Inc.

Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss, and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops innovative solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocado, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co.

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Announces Study Finding BIDI(R) Stick as Potential Satisfying Alternative for Adult Cigarette Smokers

 Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC, today announced the results of a newly published study. According to the update, the study found Bidi Vapor’s premium electronic nicotine delivery system (“ENDS”), a disposable device branded BIDI(R) Stick, mimicked the blood levels of nicotine when subjects smoked their usual brand of combustible cigarette, potentially providing a satisfying alternative to cigarette smoking. In research published in November 2021, comparative blood samples revealed a dramatic alignment between combustible cigarettes and BIDI Sticks (both tobacco and flavored products). “This study shows that the BIDI Stick can be a meaningful, nicotine delivery alternative for adult smokers aged 21 and older,” said Niraj Patel, president and chief executive officer of Bidi Vapor and Kaival Brands. “We are submitting this data to the FDA as part of our Premarket Tobacco Product Application (‘PMTA’) and believe the scientific evidence supports that the BIDI Stick is appropriate for the protection of the public health.”

To view the full press release, visit https://ibn.fm/w7jHJ

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi (R) Vapor LLC. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Inks Agreements with Leading Health and Beauty Company, CBD Beverage Company

 Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has signed a definitive agreement with Avaria Health & Beauty Corp. Based on the agreement, the two companies will form a joint venture (“JV”), named FloVaria Corp., aimed to facilitate the sale of itsaward-winning KaLaya brand; sales efforts will be directed in Latin America (“LATAM”). KaLaya has currently sold more than a million units throughout Canada and is carried in major retail locations including Walmart and Loblaws, where the brand has earned the number-two customer loyalty rating in the natural-value, skin-care category. The agreement increases the value of FLGC’s Colombian distribution channels, which currently numbers more than 2,500. The agreement calls for Flora Growth’s wholly owned, GMP-certified manufacturing facility to produce the cannabinoid-infused products that will be sold through the JV. In addition, Flora will be responsible for distribution, supply chain, and marketing support of KaLaya’s pain-management products in Colombia, Mexico and other LATAM countries, while Avaria will initially provide the finished product to the JV company. In addition, the company also announced that it is entering the cannabis beverage market. The company has entered a licensing agreement with Tonino Lamborghini to produce and distribute CBD beverages. The Tonino Lamborghini product line will launch early next year. Under the agreement, Flora Growth will retain the right of first refusal to distribute any cannabis products globally under the Tonino Lamborghini brand. “We are excited to partner with such a well-known luxury brand as Tonino Lamborghini, which already boasts a very successful line of beverages and aligns with Flora’s brand portfolio of high-end products,” said Flora Growth president and CEO Luis Merchan in the press release. “This partnership is yet another step in the execution of Flora’s strategic plan to build a world-class house of brands and is also a major component of our sales and distribution strategy in the lucrative U.S. market.”

To view the full press releases, visit https://ibn.fm/PUaLR and https://ibn.fm/3EDK4

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

 Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved key milestones. The milestones were outlined in the agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. Based on the agreement, 31,721.5 class B common shares of the company will be issued to Adelia shareholders as a result of relevant milestones being met. Adelia develops medicinal psychedelics designed to provide improved dosing efficacy and therapeutic indices that address unmet medical needs. The company’s primary focus is on the development of treatment regimens featuring proprietary psychedelic molecules and related clinical protocols.

To view the full press release, visit https://ibn.fm/8bj5e

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Expands Marketing Reach, Offers Discounts, Through New Subscription Service

 

• Plant-based food consumers are a growing market sector, increasing their purchases at a rate almost 2.5 times the growth of the overall foods market during the past two years
• Plant-based community brand builder PlantX Life Inc. is becoming a growing global presence as part of its efforts to become a one-stop shopping source of products and information about the plant-based lifestyle
• PlantX has physical store presence in Canada and the U.S., as well as one in Israel that will open before the end of the year
• The company’s e-commerce platform recently added a subscription service that caters to recurring customer services, providing discounts for automatically renewable weekly, biweekly, or monthly product shipments
• PlantX has recruited 18 social media influencers to help it market its brand to a larger segment of consumers
• The company uses a weekly podcast series, YouTube channel videos and an informative blog to help build education about the ecosystem among like-minded fans of the lifestyle

Plant-based lifestyle e-retailer and educator PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) recently announced the expansion of its online sales offerings to include discounts for shoppers who subscribe for recurring service. 

The Nov. 22 announcement states customers who arrange automatic fulfillments for recurring deliveries of any product on the PlantX website will be able to design personalized shopping plans for their favorite products with a weekly, biweekly or monthly refresher. 

“The new subscription service aims to overcome potential barriers to a healthy lifestyle such as time and cost,” PlantX Founder Sean Dollinger stated (https://ibn.fm/2SMXG).

PlantX’s focus on serving the interests of the plant-based community and providing education about its lifestyle benefits to those exploring it in North America are helping the company tap into a relatively new and growing food industry. 

Plant-based food dollar sales grew 43 percent in the past two years, at a rate almost 2.5 times faster than total food sales from 2018 to 2020, according to a report issued by Good Food Institute analysts earlier this year. The report found that the retail market for plant-based foods has risen to $7 billion, penetrating 57 percent of U.S. households (https://ibn.fm/qOBPj).

Bloomberg Intelligence valued the global market for plant-based foods at $29.4 billion in 2020 and predicted that it will exceed $162 billion within the next decade, growing at a rate of 451 percent (https://ibn.fm/PGRD7).

PlantX launched a new initiative this year to market itself to those consumers adopting aspects of the plant-based wellness lifestyle, drawing on the power of social media to get its brand more squarely in front of shoppers. 

The company has engaged select “micro-influencers” on social media platforms including TikTok and Twitter, hiring 18 influencers for limited periods to post content and provide coverage of PlantX news releases to their dedicated audiences. 

“We live in a time where brands and companies can significantly boost their popularity with viral content focused on social media apps,” PlantX Chief Marketing Officer Alex Hoffman stated in the Nov. 22 announcement. 

In addition to its e-commerce sales, PlantX has been expanding its XMarket retail store outlets, recently celebrating the grand opening of a store in the San Diego area and another in Venice Beach, which add to the company’s flagship store and dining outlet in Squamish, British Columbia. Additional stores are expected soon in Tel Aviv, Israel, and in Toronto and Ottawa, Canada (https://ibn.fm/W8E41).

As part of its efforts to become the plant-based community’s go-to one-stop-shopping hub, PlantX’s educational efforts have grown to include a weekly podcast, blog and YouTube presence, where tips on healthy diet choices, plant-growing wisdom and how to understand the ecosystem of the growing community abound. 

For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period

 AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over the same period in 2020, and gross profit margin totaling 59.3%, representing an 8.8% increase from the year before. In addition, the average selling price of ANPC’s CDA-based tests was $71.6,  an increase of 72.3% from 2020. In addition, the company reported cash and cash equivalents of approximately $0.8 million for the nine-month period. Business highlights included AnPac’s acquisition of 60% equity interest in Anpai (Shanghai) Health Management Consulting Co. Ltd. as well as continued validation regarding the efficacy of its CDA testing obtained through clinical study follow-ups. The company also completed the development and evaluation of a second-generation cancer detection sensor, launched a joint venture designed to focus on a novel cancer-treatment technology and medical-device development, and filed 261 patent applications globally, among which 150 patents have been granted. AnPac is also continuing to build a proprietary cancer-risk assessment database, which totaled some 244,310 samples as of Sept. 30, 2021. “We are very pleased with our progress in research and development, commercialization, and operational performance for the first nine months in 2021,” said AnPac Bio chair and CEO Dr. Chris Yu in the press release. “We grew revenue by 55.3% and gross margin by 8.8 percentage points. At the same time, we reduced non-GAAP loss by 6.0%. Our number of issued patents, and clinical and commercial sample sizes all reached record high in Q3 2021. We are making solid progress in obtaining regulatory approval for our class III medical device for lung cancer assisting in diagnosis and have also submitted application for registration testing of our multi-cancer detection medical device for 11 types of cancer. We are also working very hard to obtain Laboratory Developed Test (‘LDT’) status for our CDA cancer test in the U.S. Based on our current status and progress, we now expect to obtain registration approval for our class III medical device (for lung cancer assisting in diagnosis) in late 2022.”

To view the full press release, visit https://ibn.fm/a2zoT

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of Sept. 30, 2021. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection, based on approximately 43,980 clinical samples as of Sept. 30, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

 

• InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
• The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
• Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
• InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
• Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://ibn.fm/LRrGu).

On October 13, InMed closed the previously announced (https://ibn.fm/rj9qS) acquisition of BayMedica Inc., in a transaction that created an industry leader in the manufacture and commercialization of rare cannabinoids. The integrated teams are now working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry.  

“For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol(R) CBC (cannabichromene) and progressing our existing programs,” commented Eric A. Adams, InMed President and CEO.

The management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products, in addition to expanding revenues substantially in the short-to-medium term. Further, the integrated science teams will be looking to explore the therapeutic potential of BayMedica’s novel cannabinoid analogs for incorporation into InMed’s pharmaceutical drug development.

With regards to its proprietary IntegraSyn(TM) cannabinoid manufacturing approach, the team is currently focused on process optimization for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cannabinoids. InMed holds that IntegraSyn will be a preferred pharmaceutical production method and may fit perfectly with BayMedica’s chemical synthesis and biosynthesis manufacturing approaches for non-pharmaceutical applications.

In addition, September 30 also marked the beginning of the 755-201-EB study, InMed’s Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). The commencement of the study marked the first time cannabinol has advanced to a Phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment. The study, which has ethics and regulatory authority approvals in five countries and is expected to take place across seven countries, namely Austria, Germany, Greece, France, Italy, Israel, and Serbia, follows two completed Phase 1 studies.

The Phase 1 studies strongly evidenced the overall safety and tolerability of the INM-755 cream. In addition, preclinical data showed that the cream might help relieve characteristic EB symptoms, including pain and inflammation, as well as potentially restore the skin’s integrity in some EB Simplex patients. 

Combined, the activities related to the INM-755 clinical trials contributed to the company’s increased research and development (“R&D”) expenses for Q1 2022, which stood at $1.5 million, up from $0.9 million in Q1 2021.

InMed has also developed a cannabinol (“CBN”) topical eye drop formulation, INM-088, currently the subject of preclinical studies as a potential treatment for glaucoma. Data from these studies demonstrate CBN’s effectiveness in reducing cell death in retinal ganglion cells, indicating the cannabinoid’s neuroprotective capabilities that may extend vision retention. In addition, preclinical data suggest that CBN reduces intraocular pressure in glaucoma models. On August 17, the company presented at the H.C. Wainwright Ophthalmology Conference detailing these findings.

InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088.

Other key highlights of the report and business update included an international patent application for treating neurodegenerative diseases using rare cannabinoids filed early this month, as well as a notable quarter-over-quarter increase in the company’s cash, cash equivalents, and short-term investments from $7.4 million in Q4 2021 to $15.4 million in Q1 2022. InMed attributed this increase to the July 2 private placement in which the company received net proceeds of approximately $11.0 million.

For more information, visit the company’s website at www.InMedPharma.com. 

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html